September 23, 2012Current Pharmaceutical Design
Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Key result
Aspirin therapy reduces the risk of serious vascular events by about a quarter in patients with occlusive vascular disease, though its role in primary prevention remains uncertain.
Why the study?
Does aspirin reduce serious vascular events in patients with ischemic heart disease or those at high vascular risk?
Population
Patients with ischemic heart disease, acute coronary syndromes, percutaneous coronary intervention, or those…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Affirms aspirin's role in secondary prevention; leaves primary prevention benefit unresolved.
Key Points
- To evaluate the clinical efficacy, mechanisms of action, and bleeding trade-offs of aspirin therapy in both primary and secondary prevention of ischemic heart disease.
- Synthesized evidence on platelet cyclooxygenase and thromboxane A2 inhibition mediated by aspirin.
- Assessed outcomes across clinical settings including acute coronary syndromes, chronic ischemic heart disease, and percutaneous coronary intervention.
- Aspirin reduces the risk of serious vascular events by approximately 25% among high-risk patients with pre-existing occlusive vascular disease.
- Therapy is accompanied by an increased risk of major gastrointestinal and extracranial bleeds, though the absolute increase is an order of magnitude smaller than the reduction in vascular events for secondary prevention.
- The net clinical benefit of aspirin for primary prevention remains uncertain because lower baseline vascular risk does not clearly outweigh major bleeding complications.
Structured PICO
Does aspirin reduce serious vascular events in patients with ischemic heart disease or those at high vascular risk?
P
Population
Patients with ischemic heart disease, acute coronary syndromes, percutaneous coronary intervention, or those at high vascular risk considered for primary or secondary prevention
I
Intervention
Aspirin
O
Outcome
Serious vascular events and major bleeding
Aspirin remains a cornerstone for secondary prevention in ischemic heart disease, but its role in primary prevention is still debated due to the need to balance vascular benefits against bleeding risks.
Cite This Study
Caterina et al. (2012) conducted a review in Ischemic Heart Disease. Aspirin was evaluated. Aspirin therapy reduces the risk of serious vascular events by about a quarter in patients with occlusive vascular disease, though its role in primary prevention remains uncertain.